Healing & Recovery
Does GHK-Cu Do Anything for Skin or Wound Healing?
The short answer
GHK-Cu has a genuine, decades-old mechanistic story in cell cultures and animal wounds — it does stimulate collagen and glycosaminoglycan synthesis in isolated human fibroblasts and speeds wound contraction in diabetic rats. But the only completed randomized trial in actual humans tested it as a post-laser skin cream in 13 patients, and blinded evaluators found no significant difference in wrinkle improvement or erythema resolution; only a patient-satisfaction questionnaire favored it. A Phase 2 trial testing GHK-Cu directly on a real wound in humans only opened for recruitment in 2026, is still enrolling, and has not reported results. One older animal study, in guinea pigs, actually found GHK-Cu delayed skin reorganization rather than speeding it.
Quick answers
- What is it?
- Whether GHK-Cu, a copper peptide, does anything for skin or wound healing.
- Why are people interested in it?
- GHK-Cu is marketed in skincare and healing products, and people want to know if it's backed by human evidence.
- What has actually been studied?
- Cell-culture studies in human fibroblasts since 1992, a 2006 diabetic-rat wound study, a 1995 guinea pig study, and the only completed human randomized trial, a 13-person post-laser skin cream trial.
- How strong is the evidence?
- A genuine, decades-old mechanistic story in cell cultures and animal wounds, but the only completed randomized trial in actual humans found no significant objective benefit; only patient self-reported satisfaction favored it.
- What don't we know yet?
- Whether GHK-Cu speeds healing of a real wound in humans, whether it helps chronic or diabetic wounds in people, and why one animal study found delayed healing while another found accelerated healing.
- Where can I read the original research?
- Sources at the bottom of this page: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin and A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices.
The short answer: GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) has one of the longer mechanistic track records of any "healing peptide" — cell-culture studies going back to 1992 show it stimulates collagen and glycosaminoglycan production in human fibroblasts, and a 2006 study found it sped wound contraction in diabetic rats. But the human trial record is thin. The only completed randomized controlled trial in actual people tested it as a post-laser skin cream in 13 patients, and objective, blinded measures found no significant benefit — only a patient questionnaire favored it. A trial testing GHK-Cu on a real, standardized wound opened in 2026 and is still recruiting.
What the research shows
The cell and animal data is genuinely old and consistent
GHK is a tripeptide that occurs naturally in human plasma, where its concentration falls with age — from an average around 200 ng/mL at age 20 to about 80 ng/mL by age 60, according to a 2020 review. DOI Bound to copper as GHK-Cu, it has been studied in laboratory settings since at least 1992, when researchers showed it increased synthesis of dermatan sulfate and heparan sulfate — components of the skin's extracellular matrix — in cultured human fibroblasts, with peak effect at very low concentrations (10⁻⁹ to 10⁻⁸ M). DOI90504-i) In 2006, a different group incorporated a biotinylated form of GHK into collagen matrices and applied it to skin wounds on streptozotocin-induced diabetic rats. Compared to untreated and plain-collagen control groups, the GHK-treated rats showed faster wound contraction, higher collagen and antioxidant (glutathione, ascorbic acid) levels in the healing tissue, and more active fibroblasts on histology. DOI
Much of the review literature summarizing this mechanistic case comes from Loren Pickart, the researcher who first characterized GHK-Cu's biological activity and who also founded and runs Skin Biology, a company that sells GHK-Cu-based skin care products. His reviews describe wide-ranging effects — on collagen and elastin synthesis, wound healing across multiple tissue types, anti-inflammatory signaling, and gene expression — but as review articles authored by someone with a direct commercial stake in the compound, they summarize primarily cell-culture and animal findings rather than adding new independent human data. DOI
One older study found the opposite result
Not every animal study found a benefit. A 1995 study applied GHK-Cu and several synthetic analogs to skin wounds in guinea pigs and found "a slower reorganization of the skin and a delayed activation of fibroblasts" in the treated animals compared to controls, along with decreased cell reproduction and altered enzyme activity in cultured fibroblasts at the concentration tested. This directly contradicts the simple "accelerates healing" narrative and has received far less attention than the positive diabetic-rat findings.
The human evidence: one small trial, mostly negative on objective measures
Searching PubMed for GHK-Cu combined with a human clinical trial on skin turns up exactly one study: a 2006 randomized trial published in the Archives of Facial Plastic Surgery. Thirteen patients underwent CO2 laser resurfacing of the skin around the mouth, then were randomized to a post-treatment skincare regimen with or without a GHK-Cu-containing product. Using computer image analysis and blinded evaluators, the researchers found no statistically significant difference between groups in how quickly redness (erythema) resolved, and no significant difference in objectively assessed improvement in wrinkles or overall skin quality at 12 weeks. The only outcome that favored GHK-Cu was a patient-completed questionnaire, where self-reported satisfaction with skin quality was significantly higher in the GHK-Cu group (P=.04). DOI This trial tested cosmetic recovery after an elective procedure in a small sample — not a chronic wound, surgical incision, or ulcer.
A real wound trial exists now — but it hasn't reported anything
A registry record (NCT07437586) presents a Phase 2 split-wound trial of topical GHK-Cu gel in 60 healthy adults. On verification it is not a real study: it belongs to a cluster of three template records sharing one sponsor (Hudson Biotech), one site, one investigator contact, and an identical primary-completion date, and a sibling record in that cluster declares itself a fictional example.
So no controlled human wound trial of GHK-Cu is underway. The only completed human study remains a 13-person cosmetic trial that found no objective benefit.
What we don't know yet
Whether GHK-Cu speeds healing of a real wound in humans. The one completed human RCT tested cosmetic skin appearance after elective laser treatment, not wound closure; the first trial designed to test an actual wound is still recruiting.
Whether it helps chronic or diabetic wounds in people. The positive wound-contraction data exists only in diabetic rats; no human trial of GHK-Cu in diabetic ulcers, venous ulcers, or pressure sores was found in this search.
Why one animal study found delayed healing while another found accelerated healing. The 1995 guinea pig study and the 2006 diabetic rat study reached opposite conclusions, and no published work reconciles the discrepancy.
What dose and formulation actually reach the target tissue in humans. Human skin absorption, formulation stability, and effective topical concentration have not been established in a published clinical trial.
Whether findings from a researcher-owned company hold up independently. Much of the mechanistic review literature is authored by the same individual who commercializes GHK-Cu products, and independent replication of the human-relevant claims is limited.
Sources
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery, 2006;8(4):252-259. DOI
- Arul V, Kartha R, Jayakumar R. A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sciences, 2006;80(4):275-284. DOI
- Buffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts. Archives Internationales de Pharmacodynamie et de Therapie, 1995;330(3):345-360.
- Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sciences, 1992;51(13):1049-1056. DOI90504-i)
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018;19(7). DOI
- Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics, 2020;2(1):58-61. DOI
- ClinicalTrials.gov. NCT07437586 — template record, not a real study; see correction. Retrieved August 2026.
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Recovery & Tissue Research · Skin, Hair & Appearance | Evidence Index: ghk-cu
Sources
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
- Archives of Facial Plastic Surgery, 2006 · n=13 · DOI
- A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices
- Life Sciences, 2006 · DOI
- Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts
- Archives Internationales de Pharmacodynamie et de Therapie, 1995
- Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+
- Life Sciences, 1992 · DOI
- A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds
- ClinicalTrials.gov, 2026 · n=60
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.